3 June 2016 - Final recommendation is conditional on cost-effectivness being improved to an acceptable level.

CADTH has issued its final recommendation on the funding of nivolumab (Opdivo) for the treatment of adult patients with advanced or metastatic non-small-cell lung cancer with disease progression or or after cytotoxic chemotherapy. The use of Opdivo is recommended for those with advanced disease and a good performance status.

For more details, go to: https://www.cadth.ca/sites/default/files/pcodr/nivolumab_opdivo_nsclc_fn_rec.pdf